During the past decade, Universitätsklinikum Erlangen, Medizinische Klinik 5 conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Erlangen, Medizinische Klinik 5" #1 sponsor was "Hoffmann-La Roche" with 2 trials, followed by "Incyte Biosciences International Sàrl" with 1 trials sponsored, "Incyte Corporation" with 1 trials sponsored, "Technische Universität Dresden" with 1 trials sponsored and "University Hospital Muenster" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Erlangen, Medizinische Klinik 5" #1 collaborator was "Celgene Corporation" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "ClinAssess GmbH" with 1 trials as a collaborator, "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator and "Novartis Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Erlangen, Medizinische Klinik 5" are "Acute Myeloid Leukemia" (3 trials), "Accelerated Phase Chronic Myeloid Leukemia" (1 trials), "Acute Lymphoblastic Leukemia" (1 trials), "Acute Lymphocytic Leukemia" (1 trials) and "Bladder Cancer" (1 trials). Many other conditions were trialed in "Universitätsklinikum Erlangen, Medizinische Klinik 5" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Erlangen, Medizinische Klinik 5" are "Drug" (7 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Prednisone" (2 trials), "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody" (1 trials), "Cyclophosphamide" (1 trials), "Docetaxel" (1 trials) and "Doxorubicin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Erlangen, Medizinische Klinik 5" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Erlangen, Medizinische Klinik 5". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Universitätsklinikum Erlangen, Medizinische Klinik 5, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Erlangen, Medizinische Klinik 5, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".